• Langley Road, Brighton, MA
  • 416-402-8274

NIH Licensing Opportunity: Novel Diagnostic Imaging Platform to Monitor the Progression and Treatment of Metastatic Cancers


  • Start Date:October 21, 2020
  • End Date: October 21, 2020
  • Start Time:11:00 am EST
  • End Time:12:00 pm EST
  • Location:
  • Email:
  • Register


  • Start Date:October 21, 2020
  • End Date: October 21, 2020
  • Start Time:11:00 am EST
  • End Time:12:00 pm EST


This webinar already occurred on October 21, 2020 but a recording can be watched below:

Signature Square OMSIH logo

One Million Solutions in Health™ has established a one-of-a-kind partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH. This is also your opportunity to participate in our proprietary Signature Square™ process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.

Novel Diagnostic Imaging Platform

This webinar introduced a novel technology polymeric delivery platform that targets the lymphatic system through scavenger receptor A1 (SR-A1) mediated transcytosis. This receptor is highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform can deliver various diagnostic imaging compound cargo to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations that can be used to track the progression of various disease states or the progress of an associated treatment therapy. This lymphatic system targeting polymeric delivery platform is particularly well suited for diagnostic activities associated with monitoring the progression and treatment of metastatic cancers that use the lymphatic system to spread to other parts of the body.

This is an opportunity to LICENSE THIS TECHNOLOGY, or participate in further collaborative work to enhance its development.

The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like AstraZeneca, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology.

This is your opportunity to ask questions and provide feedback directly to the scientists by taking part in this Signature Square program.

Stephan T. Stern, Ph.D., DABT
Laboratory Co-Director, Director of Research & Development
Nanotechnology Characterization Laboratory
Frederick National Laboratory for Cancer Research

Dawn Van Dam
Executive Director & CEO
One Million Solutions in Health™